Yasutomi Y, Koenig S, Haun S S, Stover C K, Jackson R K, Conard P, Conley A J, Emini E A, Fuerst T R, Letvin N L
Harvard Medical School, New England Regional Primate Research Center, Southborough, MA 01772.
J Immunol. 1993 Apr 1;150(7):3101-7.
Because the transmission of HIV is likely to occur through cell-associated virus, an effective HIV vaccine should be capable of eliciting HIV-specific CTL. We have employed the simian immunodeficiency virus (SIV)/rhesus monkey model to explore the use of the attenuated tuberculosis bacillus, Calmette Guérin bacillus (BCG), as a vaccine vehicle to elicit AIDS virus-specific CTL. BCG was engineered to express SIVmac gag under the control of hsp70 regulatory sequences. Immunization with this rBCG-SIVmac gag elicited MHC class I-restricted, CD8+ SIVmac gag-specific CTL in rhesus monkeys. In fact, SIVmac gag-specific CTL could be cloned readily from peripheral blood lymphocytes of these immunized monkeys. These findings provide further evidence for the power of BCG as a vaccine vector and its continued exploration as a vehicle for eliciting HIV-specific immunity.
由于HIV的传播很可能通过细胞相关病毒发生,一种有效的HIV疫苗应能够引发HIV特异性CTL。我们采用了猴免疫缺陷病毒(SIV)/恒河猴模型,来探索使用减毒结核杆菌卡介苗(BCG)作为疫苗载体,以引发艾滋病病毒特异性CTL。对BCG进行基因工程改造,使其在hsp70调控序列的控制下表达SIVmac gag。用这种重组卡介苗-SIVmac gag免疫恒河猴,可引发MHC I类限制性、CD8 + SIVmac gag特异性CTL。事实上,很容易从这些免疫猴子的外周血淋巴细胞中克隆出SIVmac gag特异性CTL。这些发现为BCG作为疫苗载体的效力以及继续探索其作为引发HIV特异性免疫的载体提供了进一步的证据。